Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Collegium Pharmaceutical has received a notice of allowance from the US Patent and Trademark Office or USPTO for its patent application covering abuse-deterrent pharmaceutical compositions of opioids and other drugs.
Subscribe to our email newsletter
The notice of allowance is the USPTO’s official communication that the company’s application has successfully completed examination and that a patent will be issued.
Once issued, the patent will provide broad coverage for company’s abuse-deterrent, sustained-release, orally administered formulation platform, known as DETERx. Company’s lead DETERx product candidate, COL-003, a formulation of sustained release oxycodone, will be covered by the patent.